Abstract. The objective of this study comprises of developing novel co-spray dried rifampicin phospholipid lipospheres (SDRPL) to investigate its influence on rifampicin solubility and oral bioavailability. Solid-state techniques were employed to characterize the liposphere formulation. SDRPL solubility was determined in distilled water. BACTEC 460TB System was employed to evaluate SDRPL antimycobacterial activity. The oral bioavailability of the lipospheres was evaluated in Sprague Dawley rats. Lipospheres exhibited amorphous, smooth spherical morphology with a significant increase (p < 0.001) in solubility of SDRPL (2:1), 350.9 ± 23 versus 105.1 ± 12 μg/ml and SDRPL (1:1) 306.4 ± 20 versus 105.1 ± 12 μg/ml in comparison to rifampicin (RMP). SDRPL exhibited enhanced activity against Mycobacterium tuberculosis, H37Rv strain, with over twofolds less minimum inhibitory concentration (MIC) than the free drug. Lipospheres exhibited higher peak plasma concentration (109.92 ± 25 versus 54.31 ± 18 μg/ml), faster T max (two versus four hours), and enhanced area under the curve (AUC 0-∞ ) (406.92 ± 18 versus 147.72 ± 15 μg h/L) in comparison to pure RMP. Thus, SDRPL represents a promising carrier system exhibiting enhanced antimycobacterial activity and oral bioavailability of rifampicin.
INTRODUCTION
Tuberculosis (TB) is one of the most deadly diseases affecting mankind (1, 2) . It is caused by bacillus Mycobacterium tuberculosis (MTB), a facultative intracellular parasite (3, 4) . The World Health Organization (WHO) estimates that one-third of the world's population is infected with MTB. According to the WHO global TB report 2014, 1.5 million people died from TB, including 360,000 among people who were HIV-positive (5) . Although TB is reported all over the world, the highest estimated number of cases in 2013 occurred in Asia and the African Region of 56 and 29%, respectively. India and China are of the six countries that stand out as having the largest number of incident cases in the previous year. This accounts for 24 and 11% of global cases, respectively.
Rifampicin (RMP) is a frontline drug in anti-TB chemotherapy. It is a lipophillic molecule with poor aqueous solubility. RMP is a borderline class II Biopharmaceutical Classification System (BCS) drug (6) (7) (8) (9) (10) . In therapy, it is administered with isoniazid, pyrazinamide, and ethambutol for 2 months followed by a combination with isoniazid for further 4 months. Long duration of therapy causes hepatotoxicity, failure of treatment and consequently, leads to development of multidrug-resistant TB. Literature survey revealed that several approaches were reported to enhance the solubility and bioavailability of lipophillic molecules by microparticles (11) , solid dispersions (12, 13) , lipid-based formulation, (14) and cyclodextrin complexes (15) .
In the last two decades, lipid-based drug delivery systems have been extensively investigated, particularly to increase the bioavailability of BCS class II and class IV drugs. The success of Sandimmune TM and Neoral TM , the lipid-based oral products of cyclosporine A, has further intensified the interest (16) . In the lipid-based system, the drug hitherto is dissolved in the lipid excipient(s), thus enhancing the solubility of drugs with dissolution-limiting bioavailability. Phospholipids have been employed for oral delivery of therapeutics. They are biodegradable and biocompatible being the major components of the plasma membrane. Phospholipid-based systems have been developed to increase solubility and enhance dissolution rate and bioavailability of water-insoluble drugs, especially phytopharmaceuticals (17) (18) (19) (20) . Furthermore, they have been investigated to reduce NSAID-induced gastrointestinal toxicity and hepatotoxicity (21) .
In our previous work, we observed considerable enhancement in the solubility and bioavailability of RMP by preparation of its phospholipid complex using conventional solvent evaporation technique (10) , which is a time-consuming and multistep approach. Moreover, there is a clear need of an alternative method for preparation of formulation with lesser time and easy scalability. Spray drying is widely employed in microparticle preparation due to the uniform size distribution of the product and advantages of one-step formulation and drying process (22, 23) . In a quest for an industrially viable, easily scalable method with a capability of modulating the size and thereby dissolution characteristics, we have developed novel co-spray dried rifampicin phospholipid lipospheres (SDRPL) by spray drying technology. SDRPL displayed enhanced aqueous solubility and bioavailability. Further, it exhibited improved in vitro antimycobacterial activity when evaluated by the BACTEC 460TB System. Thus, this strategy is easily scalable and has the potential for oral delivery of lipospheres.
MATERIALS AND METHODS

Materials
RMP was provided by M/s. Sandoz Pharmaceuticals Ltd., Mumbai, as a kind gift sample. The phospholipid (Lipoid S-75) sample was kindly provided by Lipoid Ludwigshafen, Germany. Dichloromethane and other chemicals were obtained from Loba Chemie, Mumbai, India. Ammonium acetate was purchased from HiMedia, India. Methanol was purchased from Sigma Aldrich, Mumbai, India. All other chemicals were of analytical grade.
Preparation of SDRPLs
Three different batches of SDRPL varying drug to phospholipid ratio were prepared by spray drying (JISL Mumbai India with high-performance cyclone) a solution of RMP and PL (1:2, 1:1 and 2:1) (drug to phospholipid ratio) in dichloromethane. The feed solution was passed through a stainless steel 0.7 mm diameter atomizing nozzle via a peristaltic pump at a flow rate of 4 mL/min (pump rate 12%). The inlet temperature and outlet temperatures were set at 80 ± 2°C (primary drying step) and 55 ± 3°C (secondary drying step), respectively, with an aspirator rate of 90%. The resultant lipospheres were blown through a high-performance cyclone separator and collected in the sample container. Powder formulation was stored in glass vials sealed with parafilm at room temperature.
Drug Content and Encapsulation Efficiency
RMP content and encapsulation efficiency in the SDRPL formulation was determined using liquid chromatographymass spectrometry (LCMS) (Thermo Scientific, LTQ XL, Germany). Accurately weighed samples of the microparticles were dissolved in 10 ml of methanol followed by centrifugation for 10 min at 10,000 rpm. Subsequently, 1 ml of aliquot was taken from supernatant and analyzed using validated LCMS method. For this analysis, methanol and ammonium acetate buffer system was used in the ratio of 70:30. The Phenomenex C 18 column (250 mm × 4.6 mm, 5 μm) and flow rate was 1 mL/min at ambient temperature. The detection wavelength was 475 nm, and injection volume was 20 μl. Calculations were carried out using the equations shown below:
Solubility Study of SDRPL
The thermodynamic solubility of RMP and SDRPLs was individually studied by adding an excess amount into distilled water in sealed glass vials at 25°C and shaken in shaker water bath (EQUITRON®, Mumbai, India) for 1 h. The obtained dispersion was centrifuged at 1200 rpm for 5 min and analyzed the samples by LCMS (Thermo Scientific, LTQ XL, Germany) as previously described. All experiments were carried out in triplicate.
Thermal Analysis
The thermodynamic behavior of RMP, phospholipid, physical mixture, and SDRPL formulation was studied by differential scanning calorimetry (DSC) in Mettler Toledo DSC (821e, Switzerland) equipped with Mettler Stare system. Samples of between 3 and 5 mg were weighed in aluminum pans and hermetically sealed for analysis. For this purpose, samples were heated from 25 to 250°C using a heating rate of 10°C/min. All experiments were run under a nitrogen gas flow set at 50 ml/min. Then, phase transition temperature and the melting point (Tm) of all the samples were determined.
Crystallographic Studies
Powder X-ray diffraction (PXRD) patterns of RMP, phospholipid, physical mixture, and SDRPL formulation were acquired on an X-ray diffractometer (Bruker AXS System D8, Germany) employing Cu κ-alpha radiation (tube operated at 35 kV, 20 mA) at room temperature. Data was collected over an angular range from 2°to 40°at a step rate of 0.01 2θ scale.
Hot-Stage Cross-Polarizing Light Microscopy
The phase transitions of RMP and SDRPL formulations were observed under a cross-polarizing light hot-stage microscope (HSM) (Leitz 1350, Leica, Germany) equipped with a 35-mm camera (Leica MPS 52) for the presence and/or absence of birefringence along with the melting behavior of the samples. Powder samples were mounted on a microscope slide, placed in the sample chamber and heated from 25 to 300°C at 5°C/min heating rate.
Surface Morphology
The particle surface morphology was studied by scanning electron microscopy (SEM) in a Hitachi S-800 microscope (Tokyo, Japan). The samples were placed on aluminum stubs and coated with a thin film of gold by Technics Hummer VI sputtering system at 10 AC mA for 3 min. The samples were scanned by an electron beam of 20 kV acceleration potential, at a working distance of 30 mm. The morphological structure of the drug-encapsulated lipopsheres was investigated by transmission electron microscopy (TEM) using TECNAI G 4 microscope with an accelerating voltage of 200 kV. For the TEM analysis, carbon-coated copper TEM grids, were used.
In vitro Antimycobacterial Activity
Test Strain
The antimycobacterial activity of SDRPL and RMP was tested on MTB H37Rv strain (Tuberculosis Research Centre, Chennai, India). Briefly, the bacteria were cultured in Middlebrook 7H9 liquid medium (HiMedia, India) supplemented with 10% albumin, dextrose, and catalase (ADC; HiMedia, India) to mid-log phase and then frozen in aliquots at −70°C until needed. Purity of culture was checked by ZiehlNeelsen staining (HiMedia, India). Samples were dissolved in dimethyl sulphoxide (DMSO) and filter sterilized through 0.2-μm DMSO-Safe Acrodisc® syringe filters (PALL Life Sciences) before testing.
BACTEC 460TB Method
The BACTEC 460TB system (Becton Dickinson, USA) was employed to determine a growth index (GI) of the MTB. GI is the quantitative measure of 14 CO 2 liberated by metabolism of 14 C-labeled substrate in a medium and expressed in numbers on a scale from 0 to 999. Briefly, 0.1 ml of samples were transferred to 12B BACTEC vials, in duplicate for each sample/drug concentration, unless mentioned otherwise, and incubated at 37°C in 5% CO 2 atm. GI was calculated daily under aerobic condition until in 1:100 controls and a value greater than 30 was obtained. In order to determine the percent inhibition, undiluted control reading was used. Appropriate positive and negative controls were also included in the calculation. The growth inhibition was expressed as a ratio of GI of drug to the respective control vial. The percent growth inhibition was calculated for each drug concentration (24, 25) .
In Vivo Oral Bioavailability Study
Chromatographic Condition
The plasma RMP was quantified by LCMS (Thermo Scientific, LTQ XL, Germany) with Phenomenex C18 column (250 mm × 4.6 mm, 5 μm). The optimized mobile phase is composed of a mixture of ammonium acetate buffer (2 mM) and acetonitrile in 30:70 proportions. The flow rate was maintained at 1 mL/min, and the samples were analyzed at room temperature.
Rifampicin Extraction and Sample Preparation
To a 200-μL rat plasma sample, 500 μL of methanol was added to extract the RMP. After vortex mixing (60 s), samples were centrifuged at 10,000 rpm for 10 min. Subsequently, 20 μL supernatant was taken and analyzed by LCMS (26) .
Pharmacokinetic Studies of RMP and SDRPL
To carry out the pharmacokinetic studies, all the animal experiment protocols were approved by the Institutional Animal Ethics Committee (IAEC No. 108/1999/ CPCSEA) first and then animals studies were performed in accordance with the CPCSEA (Committee for the Purpose of Control and Supervision of Experimentation on Animals) guidelines and maintained in an air-conditioned room (25 ± 2°C) with a 12-h light/12-h dark cycle. To perform the pharmacokinetic study, one batch of SDRPL formulation (1:1) was chosen based on the physical characteristics. Food and water were provided ad libitum to all the animals. Male albino Sprague Dawley rats (150-200 g) were divided into two groups (n = 6/group/time point), one group for RMP administration (15 mg/kg dose) and the other for SDRPL administration (dose equivalent to 15 mg/kg of RMP) with the help of an oral gavage. Blood samples were collected from the retro-orbital Plexus under light ether anesthesia at various time points into heparinized micro-centrifuge vials. Then, blood samples were centrifuged at 10,000 rpm for 10 min and analyzed by LCMS. Noscapine was the internal standard employed in the estimation.
Statistical Analysis
The results are expressed as mean ± S.D. Analysis was carried out using a statistical package program (GraphPad Prism 5 for Windows).
RESULTS
Drug Content and Encapsulation Efficiency
SDRPL formulations were prepared using different ratios of phospholipid and drug. It was found that phospholipid: drug ratio significantly affected the percent drug content of the formulations. The encapsulation efficiency increased with decrease in drug to phospholipid ratio. The drug content and encapsulation efficiency were found to be in the range of 41.52 ± 4 to 53 ± 4 (% w/w) and 73 ± 6 to 89 ± 4 (% w/w), respectively.
Solubility Study
Solubility of RMP and SDRPL formulations were determined in distilled water at 25°C. There was a significant increase (p < 0.001) in the solubility of SDRPL (2:1), 360 ± 12 versus 110.05 ± 15 μg/ml, and SDRPL (1:1) 310.12 ± 20 versus 110.05 ± 15 μg/ml in comparison to RMP. This improvement in solubility can be attributed to the amorphous form of the SDRPL along with the solubilizing and surfactant effect of the phospholipid (27) (28) (29) .
Thermal Analysis
The DSC thermograms of RMP versus SDRPL formulations are presented in Fig. 1 . Pure RMP exhibited a small narrow endothermic phase transition peak, with onset temperature at d∼190°C. The melting of crystalline RMP is similar to that reported in the literature (6, 7) . This order-todisorder endothermic peak can be attributed to the melting process. These observations are in good agreement with previous reports on RMP, confirming its crystalline nature. Thermogram of phospholipid exhibited two distinct endotherms. The first endotherm was mild at 145-150°C suggesting movements of hot polar part of the phospholipid molecule. The second sharp endotherm peak at 230°C could be formed owing to the phase transition, from a gel-like to a liquidcrystal state, and perhaps due to melting of the carbon chain in the phospholipid or isomeric or crystal changes. Interestingly, DSC thermal analysis of SDRPL did not exhibit the RMP melting peak, suggesting a loss of crystallinity into a non-crystalline form (likely amorphous).
Crystallographic Analysis
Diffractograms of pure RMP and SDRPL formulations are presented in Fig. 2 . RMP revealed sharp and narrow diffraction peaks at 11°, 13.5°, 16°and 20°2θ scale, which is characteristic of a high degree of long-range molecular order (i.e., crystallinity). In the physical mixture, the diffraction peaks diminished to a certain extent. Contrastingly, in the diffractograms of SDRPL formulations, there was complete disappearance of sharp peaks, indicating loss in the crystalline nature of RMP. The loss of crystallinity of RMP following spray drying could be due to free 
HSM
To examine the phase transitions of pure RMP, crosspolarized light optical microscope analysis was performed at a heating scan rate of 5°C/min. Under cross polarizer at room temperature, RMP exhibited crystal forms as shown in Fig. 3a -e. The onset temperature coincided with its melting recorded by DSC. Unsurprisingly, SDRPL formulations exhibited softening behavior, which is a characteristic feature of amorphous materials (Fig. 4a-e) . The softening of the lipospheres started at the temperaturẽ 102°C. Nominal birefringence of RMP was detected, which agrees with the PXRD diffractograms (Fig. 5a-e) . The birefringence of pure RMP began diminishing with an increase in temperature. As expected for non-crystalline amorphous materials, the lipospheres formulation lacked birefringence, as displayed by the dark images (Fig. 6a-e) . This was in a good agreement with the DSC thermal analysis findings and PXRD results. Blue arrow shows the softening of the lipospheres and birefringence of RMP, respectively.
Surface Morphology
The particle and surface morphology of RMP and SRDPL formulations were visualized and analyzed by SEM. The micrographs are presented in Fig. 7 . RMP exhibited rod and columnar non-spherical morphology (Fig. 7a) (6) . The lipospheres formulation at 1:1 ratio presented spherical particles with a smooth surface (Fig. 7b) . On the contrary, the 2:1 and 1:2 ratios exhibited a little and great degree of aggregation as observed in 
Transmission Electron Microscopy Analysis
TEM is employed for visualizing the surface morphology and size of the drug encapsulated lipospheres in water at room temperature. TEM analysis is ultimate for quantitatively visualizing the surface texture of the substance. TEM image of lipospheres is shown in Fig. 7e , wherein nanosized particles with average size of 231-250 nm were observed. These results suggest that phospholipids may serve as efficient delivery carriers for hydrophobic drugs.
In Vitro Antimycobacterial Activity
Two SDRPL formulations (1:1 and 2:1 proportions of drug to lipid) were selected based on surface morphology and ease of preparation and tested for antimycobacterial activity. Both the formulations exhibited enhanced efficacy in vitro in MTB H37Rv strain. DMSO was employed as the solubilizing agent and its possible inhibitory effect on MTB growth was considered, as well. There was a significant difference (p < 0.001) between minimum inhibitory concentration (MIC) values of RMP and SDRPL formulations against MTB, and it was found to be 0.025 (31) and 0.010 μg/ml, respectively. Thus, lipospheres formulation exhibited an enhanced antimycobacterial activity. This enhancement can be explained by an increase in surface area and stability of RMP and a potential solubi- lizing effect of phospholipid. This is the first time that activity of a liposphere formulation of RMP has been reported. Figure 8 presents the plasma concentration versus time plots of RMP (15 mg/kg) and SDRPL formulation (equivalent to 15 mg/kg of RMP) after oral administration in SD rats. The lipospheres formulation exhibited increased C max (109.92 ± 25 versus 54.31 ± 18 μg/ml) and faster T max (2 versus 4 h) in comparison to pure RMP. Similarly, the area under the curve (AUC 0-∞ ) value was 406.92 ± 18 versus 147.72 ± 15μgh/L in the lipospheres and RMP, respectively. Thus, a 275% increase was observed in the relative oral bioavailability of RMP in the liposphere formulation. Pharmacokinetic study data is compiled in Table I. RMP is a potential substrate for P-glycoprotein (Pgp) efflux (32) since P-gp substrates are cationic, hydrophobic molecules with at least two planar rings and molecular weights of 400-1500. Due to P-gp efflux action, RMP bioavailability is limited. This enhanced bioavailability can be explained by (1) the formation of selfassembled micelles of phospholipid lipospheres. The micelles increased the solubility and prevented the degradation of RMP in the gastrointestinal tract resulting in enhanced bioavailability by modifying the cell fluidity (33) . In addition to this, micellar system bypass the Pgp efflux since transportation occurs through receptormediated endocytosis in comparison to diffusion for free drug into the cell (34, 35) .
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(2) RMP is a potent enzyme inducer and induces its own metabolism which could decrease its bioavailability and efficacy (36) . Addition into phospholipid matrix could limit its own metabolism, thereby increasing oral bioavailability. However, the reason for enhanced bioavailability via this mechanism is under investigation. 
CONCLUSIONS
In the present study, we reported microscale RMP lipospheres, SDRPL, for oral delivery. The particle and surface morphologies of RMP and SDRPL were studied by SEM. DSC and PXRD analyses were employed to study changes in physical characteristics after processing. HSM study further confirms the change from crystalline to amorphous form in the lipospheres formulation. TEM analysis showed nanosized particles with average size of 230-250 nm. In vitro antimycobacterial studies of SDRPL indicated its enhanced efficacy. It can be produced by an industrially viable, easily scalable technology with capability for modulating the size and functions. Thus, this can be concluded that novel SDRPL has exhibited increased antimycobacterial activity and oral bioavailability.
